TITLE

The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration

AUTHOR(S)
Azad, Rajvardhan; Chandra, Parijat; Gupta, Ritesh
PUB. DATE
November 2007
SOURCE
Indian Journal of Ophthalmology;Nov2007, Vol. 55 Issue 6, p441
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Age-related macular degeneration (ARMD) is the most common cause for visual impairment in the elderly in western countries. Recently several anti-vascular endothelial growth factor (VEGF) drugs like pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin) are available for use in the management of wet ARMD. A major limitation of these drugs is that they require multiple intravitreal injections, every 4 to 6 weeks interval for a period of 2 years. Moreover, most of these drugs are too expensive for the general masses to afford in developing nations. Avastin, though used "off-label", offers a comparable result at affordable cost, however, long term results are awaited. The drug industry should review the entire pricing policy of these drugs in developing countries like India, and develop affordable alternative compounds. The article reviews the economic burden and affordability issues of these Anti-VEGF drugs in ARMD.
ACCESSION #
27260101

 

Related Articles

  • Comparison studies of anti-VEGF agents a 'global effort'. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p25 

    The article reports on the presentation by doctor Daniel F. Martin on the comparison studies and international effort to understand the differences between the two anti-vascular endothelial growth factor (VEGF) agents, ranibizumab and bevacizumab.

  • Anti-VEGF injections may not be preferred for AMD patients with poor baseline visual acuity. Pagnani, Michelle // Ocular Surgery News;3/25/2012, Vol. 30 Issue 6, p10 

    The article reports on a study which found that for those with age-related macular degeneration and poor baseline acuity, consideration of an alternative to anti-vascular epithelial growth factor (VEGF) therapy may be warranted.

  • Novel therapy targets integrin receptors. Karageozian, Vicken // Ophthalmology Times;Oct2015, Vol. 40 Issue 17, p42 

    The article discusses the result of the clinical trial of ALG-1001 from Allegro Ophthalmics for the treatment of vitreoretinal disease. Topics covered include the comparability of ALG-1001 to that of anti-vascular endothelial growth factor agents, the reasons for targeting integrins in...

  • Silicone deposits in repackaged anti-VEGF may cause permanent IOP spikes. Kahook, Malik Y. // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p15 

    The article focuses on the occurrence of intraocular pressure (IOP) spikes of patients that receive intravitreal injections, wherein it is said that IOP spikes is due to the silicone oil deposits that leach from the repackage vials of anti-vascular endothelial growth factor (VEGF) agents.

  • Combining anti-PDGF with anti-VEGF may improve visual acuity, reduce AMD treatment burden.  // Ocular Surgery News;7/25/2012, Vol. 30 Issue 14, Special section p1 

    The article states that the complex disease process 'Advanced age-related macular degeneration be treated by modulating two factors 'VEGF' and 'PDGF'.When anti VEGF therapy is combined with anti platelet derived growth factor aptamer it leads to a better visual outcome.The limitation of anti...

  • Ranibizumab: points to consider when using it to treat neovascular age-related macular degeneration according to EU labelling. Lyseng-Williamson, Katherine; Frampton, James // Drugs & Therapy Perspectives;Sep2013, Vol. 29 Issue 9, p268 

    Ranibizumab (Lucentis), an inhibitor of multiple vascular endothelial growth factor A isoforms, is approved for the intravitreal treatment of neovascular (wet) age-related macular degeneration (AMD). In clinical trials in patients with neovascular AMD, monthly or less frequent injections of...

  • Clinical Diagnosis. Managing retinal vaso-occlusive diseases. Groves, Nancy; Suñer, Ivan J. // Ophthalmology Times;10/15/2014, Vol. 39 Issue 19, p36 

    The article reviews a study that determined the effectivity of ranibizumab injection through an ultra-widefield fluorescein angiography-guided injection for branch retinal vein occlusion (BRVO) in patients with macular edema. Topics covered include ranibizumab blocking vascular endothelial...

  • Ranibizumab and the eye. Noble, Jason; Chaudhary, Varun // CMAJ: Canadian Medical Association Journal;4/19/2011, Vol. 183 Issue 7, p822 

    The article offers information on the use of the VEGF-A inhibitor ranibizumab as treatment for wet age-related macular degeneration. It states that several large randomized controlled trials have been conducted to examine the efficacy and safety of ranibizumab. It also says that systemic adverse...

  • Age-related macular degeneration. Ong, B. B.; Ah-Fat, F. G. // British Journal of Hospital Medicine (17508460);Feb2016, Vol. 77 Issue 2, pC18 

    The article discusses clinical information on age-related macular degeneration (AMD). Topics explored include the percentage of visual impairment cases in Great Britain which may be attributed to AMD, pathophysiological factors which characterize geographic atrophy and exudative AMD, and...

  • Frequency of anti-VEGF treatment trends toward extended intervals.  // Ocular Surgery News;2/25/2014, Vol. 32 Issue 4, p1 

    The article reports that anatomic changes detected on spectral-domain optical coherence tomography will be considered in deciding to retreat patients with age-related macular degeneration with anti-vascular endothelial growth factor (VEGF) injections according to ophthalmologist Dr. Elias Reichel.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics